130 related articles for article (PubMed ID: 26180928)
1. Gene therapy with SOCS1 for gastric cancer induces G2/M arrest and has an antitumour effect on peritoneal carcinomatosis.
Natatsuka R; Takahashi T; Serada S; Fujimoto M; Ookawara T; Nishida T; Hara H; Nishigaki T; Harada E; Murakami T; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Kishimoto T; Mori M; Doki Y; Naka T
Br J Cancer; 2015 Jul; 113(3):433-42. PubMed ID: 26180928
[TBL] [Abstract][Full Text] [Related]
2. Suppressor of cytokine signaling-1 gene therapy induces potent antitumor effect in patient-derived esophageal squamous cell carcinoma xenograft mice.
Sugase T; Takahashi T; Serada S; Nakatsuka R; Fujimoto M; Ohkawara T; Hara H; Nishigaki T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Kishimoto T; Mori M; Doki Y; Naka T
Int J Cancer; 2017 Jun; 140(11):2608-2621. PubMed ID: 28233302
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative effect of SOCS-1 through the suppression of STAT3 and p38 MAPK activation in gastric cancer cells.
Souma Y; Nishida T; Serada S; Iwahori K; Takahashi T; Fujimoto M; Ripley B; Nakajima K; Miyazaki Y; Mori M; Doki Y; Sawa Y; Naka T
Int J Cancer; 2012 Sep; 131(6):1287-96. PubMed ID: 22095154
[TBL] [Abstract][Full Text] [Related]
4. BTG1 expression correlates with pathogenesis, aggressive behaviors and prognosis of gastric cancer: a potential target for gene therapy.
Zheng HC; Li J; Shen DF; Yang XF; Zhao S; Wu YZ; Takano Y; Sun HZ; Su RJ; Luo JS; Gou WF
Oncotarget; 2015 Aug; 6(23):19685-705. PubMed ID: 26050197
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy with SOCS1 induces potent preclinical antitumor activities in oral squamous cell carcinoma.
Nakatani K; Serada S; Fujimoto M; Obata K; Ohkawara T; Sasabe E; Yamamoto T; Naka T
J Oral Pathol Med; 2022 Feb; 51(2):126-133. PubMed ID: 34878693
[TBL] [Abstract][Full Text] [Related]
6. Combination DLL4 with Jagged1-siRNA can enhance inhibition of the proliferation and invasiveness activity of human gastric carcinoma by Notch1/VEGF pathway.
Sun HW; Wu C; Tan HY; Wang QS
Hepatogastroenterology; 2012 May; 59(115):924-9. PubMed ID: 22020917
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy using ets-1 transcription factor decoy for peritoneal dissemination of gastric cancer.
Taniguchi H; Fujiwara Y; Doki Y; Sugita Y; Sohma I; Miyata H; Takiguchi S; Yasuda T; Tomita N; Morishita R; Monden M
Int J Cancer; 2007 Oct; 121(7):1609-17. PubMed ID: 17546598
[TBL] [Abstract][Full Text] [Related]
8. ICAM-2 gene therapy for peritoneal dissemination of scirrhous gastric carcinoma.
Tanaka H; Yashiro M; Sunami T; Sakate Y; Kosaka K; Hirakawa K
Clin Cancer Res; 2004 Jul; 10(14):4885-92. PubMed ID: 15269165
[TBL] [Abstract][Full Text] [Related]
9. Adenoviral oncolytic suicide gene therapy for a peritoneal dissemination model of gastric cancer in mice.
Imamura Y; Ishikawa S; Sato N; Karashima R; Hirashima K; Hiyoshi Y; Nagai Y; Koga Y; Hayashi N; Watanabe M; Yamada G; Baba H
Ann Surg Oncol; 2010 Feb; 17(2):643-52. PubMed ID: 20012217
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-19a functions as an oncogenic microRNA in non-small cell lung cancer by targeting the suppressor of cytokine signaling 1 and mediating STAT3 activation.
Wang X; Chen Z
Int J Mol Med; 2015 Mar; 35(3):839-46. PubMed ID: 25604748
[TBL] [Abstract][Full Text] [Related]
11. Cathepsin B cleavable novel prodrug Ac-Phe-Lys-PABC-ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis: an experimental study.
Shao LH; Liu SP; Hou JX; Zhang YH; Peng CW; Zhong YJ; Liu X; Liu XL; Hong YP; Firestone RA; Li Y
Cancer; 2012 Jun; 118(11):2986-96. PubMed ID: 22006342
[TBL] [Abstract][Full Text] [Related]
12. SOCS1 Gene Therapy for Head and Neck Cancers: An Experimental Study.
Kajiyama T; Serada S; Fujimoto M; Ohkawara T; Komori M; Hyodo M; Naka T
Anticancer Res; 2022 Jul; 42(7):3361-3372. PubMed ID: 35790291
[TBL] [Abstract][Full Text] [Related]
13. Corilagin inhibits hepatocellular carcinoma cell proliferation by inducing G2/M phase arrest.
Ming Y; Zheng Z; Chen L; Zheng G; Liu S; Yu Y; Tong Q
Cell Biol Int; 2013 Oct; 37(10):1046-54. PubMed ID: 23686743
[TBL] [Abstract][Full Text] [Related]
14. Intraperitoneal administration of a small interfering RNA targeting nuclear factor-kappa B with paclitaxel successfully prolongs the survival of xenograft model mice with peritoneal metastasis of gastric cancer.
Inoue M; Matsumoto S; Saito H; Tsujitani S; Ikeguchi M
Int J Cancer; 2008 Dec; 123(11):2696-701. PubMed ID: 18798274
[TBL] [Abstract][Full Text] [Related]
15. Treatment of peritoneal carcinomatosis with intraperitoneal administration of Ad-hARF.
Rajeshkumar BR; Paliwal S; Lambert L; Grossman SR; Whalen GF
J Surg Res; 2015 Jul; 197(1):85-90. PubMed ID: 25935465
[TBL] [Abstract][Full Text] [Related]
16. Effects of suppressor of cytokine signaling 1 silencing on human melanoma cell proliferation and interferon-γ sensitivity.
Xu Y; Wang W; Gou A; Li H; Tian Y; Yao M; Yang R
Mol Med Rep; 2015 Jan; 11(1):583-8. PubMed ID: 25322862
[TBL] [Abstract][Full Text] [Related]
17. Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer.
Namiki Y; Namiki T; Yoshida H; Date M; Yashiro M; Matsumoto K; Nakamura T; Yanagihara K; Tada N; Satoi J; Fujise K
Int J Cancer; 2006 Mar; 118(6):1545-55. PubMed ID: 16206271
[TBL] [Abstract][Full Text] [Related]
18. Transduction of soluble Flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer.
Sako A; Kitayama J; Koyama H; Ueno H; Uchida H; Hamada H; Nagawa H
Cancer Res; 2004 May; 64(10):3624-8. PubMed ID: 15150121
[TBL] [Abstract][Full Text] [Related]
19. Tumour-derived IL-10 within tumour microenvironment represses the antitumour immunity of Socs1-silenced and sustained antigen expressing DCs.
Song S; Wang Y; Wang J; Lian W; Liu S; Zhang Z; Liu F; Wei L
Eur J Cancer; 2012 Sep; 48(14):2252-9. PubMed ID: 22230748
[TBL] [Abstract][Full Text] [Related]
20. Treatment of experimental murine pancreatic peritoneal carcinomatosis with fibroblasts genetically modified to express IL12: a role for peritoneal innate immunity.
Péron JM; Bureau C; Gourdy P; Lulka H; Souque A; Calippe B; Selves J; Al Saati T; Bernad J; Cordelier P; Couderc B; Pradayrol L; Pipy B; Buscail L; Vinel JP
Gut; 2007 Jan; 56(1):107-14. PubMed ID: 16891358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
